Cart
sales@molnova.com
Home - Products - GPCR/G Protein - LPA Receptor - Ki16425

Ki16425

CAS No. 355025-24-0

Ki16425( Ki16425 | Ki-16425 | Ki 16425 )

Catalog No. M14214 CAS No. 355025-24-0

Ki16425 is a competitive, potent and reversible antagonist to LPA1, LPA2 and LPA3 with Ki of 0.34 μM, 6.5 μM and 0.93 μM, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 47 In Stock
10MG 81 In Stock
25MG 178 In Stock
50MG 348 In Stock
100MG 487 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Ki16425
  • Note
    Research use only, not for human use.
  • Brief Description
    Ki16425 is a competitive, potent and reversible antagonist to LPA1, LPA2 and LPA3 with Ki of 0.34 μM, 6.5 μM and 0.93 μM, respectively.
  • Description
    Ki16425 is a competitive, potent and reversible antagonist to LPA1, LPA2 and LPA3 with Ki of 0.34 μM, 6.5 μM and 0.93 μM, respectively, shows no activity at LPA4, LPA5, LPA6.
  • In Vitro
    Ki16425 (10 μM; 1.5 hours; HEK293A cells) treatment blocks LPA-induced dephosphorylation of YAP/TAZ in HEK293A cells. Ki16425 partially inhibits the ability of serum to repress YAP/TAZ phosphorylation, particularly at low serum concentrations (0.2%). Western Blot Analysis Cell Line:HEK293A cells Concentration:10 μM Incubation Time:1.5 hours Result:Blocked LPA-induced dephosphorylation of YAP/TAZ. Partially inhibited the ability of serum to repress YAP/TAZ phosphorylation.
  • In Vivo
    Ki16425 (Debio 0719) (1-30 mg/kg; i.p.; at 30 min prior to LPA injection) inhibits LPA-induced neuropathic pain-like behaviors. Animal Model:20-24 g male standard ddY-strain mice Dosage:1-30 mg/kg Administration:Intraperitoneal injection; at 30 minutes prior to LPA injection Result:LPA-induced neuropathic pain behaviors were attenuated in a dose-dependent manner.
  • Synonyms
    Ki16425 | Ki-16425 | Ki 16425
  • Pathway
    GPCR/G Protein
  • Target
    LPA Receptor
  • Recptor
    LPA1| LPA2| LPA3
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    355025-24-0
  • Formula Weight
    474.96
  • Molecular Formula
    C23H23ClN2O5S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:95 mg/mL (200.01 mM); Ethanol:95 mg/mL (200.01 mM); Water:<1 mg/mL (<1 mM)
  • SMILES
    O=C(O)CCSCC1=CC=C(C2=C(NC(OC(C3=CC=CC=C3Cl)C)=O)C(C)=NO2)C=C1
  • Chemical Name
    3-((4-(4-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-3-methylisoxazol-5-yl)benzyl)thio)propanoic acid

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Ohta H, et al, Mol Pharmacol, 2003, 64(4), 994-1005.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • AM095 free acid

    AM095 (free acid) is a potent LPA1 receptor antagonist (IC50s: 0.98 and 0.73 μM for recombinant human or mouse LPA1).In vitro, AM095 was a potent LPA receptor antagonist because it inhibited GTPγS binding to Chinese hamster ovary (CHO) cell membranes overexpressing recombinant human or mouse LPA with IC values of 0.98 and 0.73 μM, respectively, and exhibited no LPA agonism.

  • Radioprotectin-1

    Radioprotectin-1 is a selective agonist of LPA2 with EC50 of 25 nM for murine LPA2 GPCR and exerts radioprotective and radiomitigative action.

  • Ki16198

    Ki16198 is the methyl ester of Ki16425 which is a LPA antagonist and inhibits LPA1- and LPA3-induced inositol phosphate production with Ki of 0.34 μM and 0.93 μM.

Sign In Join Free